A randomized study of mitoxantrone plus cytarabine versus daunomycin plus cytarabine in the treatment of previously untreated adult patients with acute nonlymphocytic leukemia
Clicks: 123
ID: 118605
1970
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
123 views
9 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #76 of 85 articles by views in Annals of hematology
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Between May 1985 and November 1988, 143 adult patients with previously untreated acute nonlymphocytic leukemia were randomized to receive mitoxantrone and cytarabine (MTT+Ara-C) or daunomycin and cytarabine (DNM+Ara-C) in order to compare the efficacy and acute and chronic toxicities. Therapy consisted of 3 days of MTT 12 mg/m2/i.v. or DNM 45 mg/m2/i.v.; both groups received Ara-C 100 mg/m2 daily by continuous infusion (CI) for 7 days. Those who failed to achieve a complete remission after one induction course received a second induction course for 2 and 5 days at the same doses. All the patients who achieved complete remission received two consolidations of 2 days of MTT or DNM and 5 days of Ara-C in CI at the same dose as for induction. Of the 72 patients on MTT+Ara-C, 38 (53%) achieved complete remission, compared with 29 (43%) of 67 treated with DNM+Ara-C. Three and 5 patients had partial remission, 7 and 18 failed to respond, 24 and 15 died in the first 21 days of induction, of those treated with MTT+Ara-C or DNM+Ara-C, respectively (p=0.34). Median duration of complete remission and survival was 185 and 103 days or 165 and 160 days, respectively (p=0.85). More early deaths were observed with MTT+Ara-C due to greater myelosuppression, and a higher incidence of failure with DNM+Ara-C. No significant differences between treatment groups were observed in 21 categories of adverse events. The results demonstrate similar incidence of complete response, length of duration of complete remission, overall survival, and toxicity with MTT+Ara-C and DNM+Ara-C.
| Reference Key |
pavlovsky1970annalsa
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | S. Pavlovsky;J. Gonzalez Llaven;M. A. Garcia Martinez;P. Sobrevilla;M. Eppinger-Helft;A. Marin;M. López-Hernández;I. Fernandez;M. E. Rubio;S. Ibarra;M. Lluesma;G. Ruiz Arguelles;F. José de Diego;S. Pavlovsky;J. Gonzalez Llaven;M. A. Garcia Martinez;P. Sobrevilla;M. Eppinger-Helft;A. Marin;M. López-Hernández;I. Fernandez;M. E. Rubio;S. Ibarra;M. Lluesma;G. Ruiz Arguelles;F. José de Diego; |
| Journal | Annals of hematology |
| Year | 1970 |
| DOI |
doi:10.1007/BF01757342
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.